Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?
The beneficial effects of empagliflozin have been published as it relates to all-cause and cardiovascular mortality. Do these effects hold true for other SGLT2 inhibitors?
The study, published in The Journal of Clinical Endocrinology and Metabolism, was a retrospective cohort study of over 22,000 patients with T2DM from the UK in The Health Improvement Network Database (Jan 2013 – Sept 2015). Researchers compared exposed patients (those given dapagliflozin) to unexposed patients (dapagliflozin-naÃ¯ve).
Patients on dapagliflozin were significantly less likely to die from any cause, regardless of baseline cardiac risk.